Temperature Control after Cardiac Arrest

Aim To provide guidance on therapeutic temperature control in Critical Care to improve neurological outcome after cardiac arrest

Scope All patients admitted to Critical Care after witnessed VT/VF arrest. Patients with non-VT/VF arrest may also be included at the discretion of the duty consultant for Critical Care.

Goals of Temperature Control
1. Rapidly achieve and maintain a core body temperature of 36°C when circulation is restored after arrest.
2. Maintain this temperature at a steady state for 30 hours after the initiation of temperature control.
3. Provide an excellent standard of critical care support and other neuroprotective measures.

Unconscious Cardiac Arrest Survivor

VF/Pulseless VT

Achieve and maintain target temp 36°C using passive rewarming or cold IV Hartmann’s as appropriate

Transfer to Critical Care ASAP for 30 hours of temperature control.

PEA/Asystole or unable to maintain BP or unknown arrest duration

Discuss with duty Critical Care Consultant

Admit for support without temperature control or switch to palliative care

Temperature Control at 36°C
- Use Coolguard device set to 36°C in Critical Care
- If patient presents cold, allow controlled rewarming to 36°C at 0.5°C/h using Coolguard.
- Establish continuous temperature monitoring
- Maintain deep sedation using propofol + opioid
- Use lactate clearance to guide shock resuscitation
- Control shivering with surface warming or neuromuscular blocking drugs
- Maintain standard neuroprotective measures including MAP >80 mmHg, normoglycaemia, normal PaO₂ (8-12 kPa) and normal PaCO₂ (4.5-5.3 kPa)

Rewarming
- Stop sedation 30 hrs after initiation of therapeutic normothermia.
- Use continued active cooling to prevent rebound hyperthermia. This should be vigorously guarded against, e.g., by using Coolguard set at 36.5-37°C for 24 hrs after the first 30 hr period has finished.
TABLE OF CONTENTS

1. Introduction
2. Purpose
3. Scope
4. Definitions
5. Duties and Responsibilities
6. Process
7. Training Requirements
8. Monitoring Compliance with, and the Effectiveness of Procedural Documents
9. References and Associated Documents

Appendix A. Neuroprognostication of Cooled Arrest Survivors
Appendix B. Laerdal Medicool Kit – Instructions for Preparation and Use
Appendix C. Checklist for the Review and Ratification of Procedural Documents and Consultation and Proposed Implementation Plan
Appendix D. Equality Impact Assessment
1. INTRODUCTION

Mild therapeutic hypothermia had been shown to be the most important post cardiac arrest therapy to reach clinical application in recent times.\(^1\) After successful animal studies in the 1980’s, three randomised control trials (RCTs) reported higher rates of favourable neurological outcome associated with the use of mild hypothermia.\(^2,3,4\) The largest study also observed an increase in survival. A subsequent Meta analysis\(^5\) concluded that the number needed to treat for patients in cardiac arrest with an initial rhythm of VF/VT was six. The TTM trial has subsequently confirmed that control to 36\(^\circ\)C is equally effective as 33\(^\circ\)C.\(^16\)

2. PURPOSE

The purpose of this guideline is to provide an evidence-based framework for use in critically ill patients with the aim of improving their neurological outcome following witnessed VT/VF cardiac arrest.

3. SCOPE

This guideline applies to all critical care patients admitted to DCCQ following witnessed VT/VF cardiac arrest, including patients admitted via ED and other ward areas. This should be implemented at the earliest opportunity possible by experienced practitioners e.g. by the ED senior medic or critical care transfer team. Subsequent management should continue in the critical care department and should be the responsibility of experienced medical and nursing personnel. This guideline is subject to professional judgement and accountability.

4. DEFINITIONS

AHA: American Heart Association  
DCCQ: Department of Critical Care Queen Alexandra Hospital  
DNAR: Do Not Attempt Resuscitate  
ED: Emergency Department  
ERC: European Resuscitation Council  
HME: Heated moisture exchange filter  
ILCOR: International Liaison Committee on Resuscitation  
IV: Intra-Venous  
MAP: Mean Arterial Pressure  
OOH: Out of Hospital  
PEA: Pulseless Electrical Activity  
RCT: Randomised Control Trial  
ROSC: Return of Spontaneous Circulation  
TOF: Train of Four  
VF: Ventricular Fibrillation  
VT: Ventricular Tachycardia

5. DUTIES AND RESPONSIBILITIES

- The decision to implement this guideline is at the discretion of the on-call critical care consultant.  
- Implementation of this guideline is the joint responsibility of appropriate critical care medical/nursing staff.  
- This guideline is subject to professional judgment and accountability.  
- Subsequent medical management may be influenced by predicted neurological outcome (see appendix 1)
### 6. PROCESS

<table>
<thead>
<tr>
<th>Action</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion Criteria</strong></td>
<td>Only this group of patients have been shown to benefit from temperature control. The duration of arrest correlates poorly with outcome.</td>
</tr>
</tbody>
</table>
| *Witnessed cardiac arrest in VT/VF with ROSC in or out of hospital*  
* Unconscious patient with no responses to pain or eye opening (no waiting period required)  
* Systolic blood pressure of 90mmHg maintained with or without fluids and/or Inotropes | To prevent further neurological impairment. |
| **Exclusion Criteria** | There is no proven clinical benefit in these situations. Scandinavian Society of Anaesthesiology and Intensive Care Medicine (SSAI) recommend that cooling should not necessarily be ruled out in these cases, but there is conflicting evidence. |
| *Other causes of coma e.g. status epilepticus, hypoglycaemia*  
*Known terminal illness*  
*Valid DNAR status*  
*Active haemorrhage*  
*Isolated respiratory arrest without cardiac arrest*  
*Refractory shock unresponsive to Inotropes*  
*PEA/Asystole should only be cooled after discussion with the DCCQ consultant in charge* | |
| **Pre DCCQ Guidance** | For airway protection and to minimise neurological activity |
| *Patients should be intubated and ventilated using appropriate drugs if necessary.*  
*Patients should be maintained strictly at 36°C once the above criteria are met*  
*Cooling must commence in the ED for OOH arrest or at the site of resuscitation for intra-hospital arrest in the event of presentation over 36°C*  
*Patients in refractory shock unresponsive to inotropes should be discussed with the duty DCCQ consultant as soon as possible*  
*To achieve immediate cooling in patients over 36°C use up to 30ml/kg Hartmann’s solution stat IV at 4 degrees Celsius via **peripheral** cannula. (This is kept in fridges in ED)*  
*Dysrhythmias or pulmonary oedema are rare and do not preclude cold IV fluids*  
*Record clearly the time ROSC was achieved or the time of admission if unknown* | 36°C in accordance with the TTM trial. This is done rapidly to maximise neurological protection. To maximise the benefit of cooling on neurological outcome. No proven clinical benefit at present |
| | Almost all arrests actually present cold, but fever is deleterious. Immediate cooling is best achieved using cold IV fluids. Central line administration of cold fluids risks cardioplegia. Cooling below 30°C can precipitate dysrhythmias. To accurately time 30°C of normothermia to 36°C |
Pre DCCQ Guidance (continued)

*Rectal, bladder, oesophageal or tympanic (not axillary) temperature should be monitored continuously

In DCCQ Guidance

*The patient should be mechanically ventilated but the ventilator humidifier turned off. HME filters can be used instead

*Propofol should be used in acute brain injury to maintain a sedation score of -4 (Please refer to DCC peripheral nerve stimulator and sedation guidelines)

*Arterial pressure should be monitored and a MAP >80 mmHg maintained with fluids and vasopressors. Hypotension must be avoided. Cooling will raise MAP.

*Use lactate clearance and SvO2 to assess shock resolution. Do not target CI>3.5.

*Proceed with the insertion of the 'IcyCath' central venous cooling catheter (refer to detailed instructions on catheter insertion) and use of ‘coolguard’ system (instructions attached to machine). **Insertion of IcyCath should be by an experienced practitioner** e.g. DCC Registrar or Consultant.

*Aim to achieve core temperature of 36°C for 30 hrs

*The medicool cooling kit is placed as per enclosed instructions (see appendix 2)

To achieve accurate recording of temperature

Use of a heated humidified circuit with the ventilator, could further increase patient temperature

To promote patient comfort, prevent shivering and to minimise neurological activity Midazolam should be reserved for unstable CVS. Propofol is redistributed whereas midazolam metabolism is cytochrome dependent and may therefore be prolonged.

To maintain adequate circulation, renal and cerebral perfusion. CI is unreliable in cooled subjects as the HR falls, but cardiac performance improves whilst cooled. Clinical signs of hypoperfusion are also unreliable. Serial echocardiography may be useful before commencing inotropes.

This is the preferred temperature control equipment for DCCQ. Equipment consumable costs are high and it is important to achieve a first-time successful line placement where possible.

TTM Trial protocol

These are other accepted methods for cooling if the patient exceeds 36°C and the IcyCath is unavailable.
<table>
<thead>
<tr>
<th>...In DCCQ Guidance (continued)</th>
<th>Guidelines as per ILCOR, ERC and AHA recommendations (^6,7,8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Shivering may occur during cooling. Shivering can be controlled with surface counterwarming using a warm air blanket or with neuromuscular blocking drugs given as a bolus, with or without infusion. TOF monitoring must be used if these drugs are used. (Please refer to DCCQ peripheral nerve stimulator and sedation guideline). Tramadol, Pethidine and Magnesium Sulphate have also been used successfully. Seek senior medical advice if shivering persists</td>
<td>Shivering may prevent patient from ventilating adequately, prevent accurate monitoring, cause patient discomfort, will increase overall oxygen consumption and may cause patient’s temperature to rise or plateau (or prevent it from lowering). Surface warming will stop shivering without raising core temperature if IV normothermia is used, particularly over the hands, feet and face. (^7)</td>
</tr>
</tbody>
</table>
| *Cardiac medications including aspirin, anti-arrhythmias, thrombolysis and cardiac catheterisation/PCI should be considered urgently if indicated. Seek senior medical advice prior to administering | To prevent cardiac instability and to commence secondary protection against further MI \(^11\) \(^11\) \(^11\) \(^11\) \(^11\)
See DCCQ Standard Operating Procedure on PCI in Critical Care patients. |
| *If cardiac catheterisation is considered avoid cannulating the right radial or femoral arteries if possible | These are preferred sites for cardiac catheterisation \(^11\) \(^11\) |
| *Temperature rises should be identified and treated. Seek senior medical advice if cooling techniques do not lower temperature. Use the graph function on the CoolGuard to assess how hard it is working to achieve hypothermia. | Even short rises in temperature may worsen neurological outcome. \(^6\) |
| *Critical care nursing should include specific attention to care related to immobility and potential for raised intracranial pressure e.g. pressure area care and neuroprotective measures | Prevention of pressure areas due to immobility and cooling. |
| *Avoid hypoxia, superoxia and hypocarbia. Aim for PaO2 8-12 kPa and normocarbia PaCO2 4.5-5.3 kPa. | Accepted neuroprotective measures include 30 degree head elevation, ET tube secured with tape, Et\(^CO_2\) 4.5kpa\(^12\) There is a U shaped survival curve with worse mortality at extremes of PaO\(_2\) and PaCO\(_2\) . |
| *There is no evidence that feeding during the cooling period has any benefit. There is a risk of overfeeding as the metabolic rate is greatly reduced. Usual feeding should commence after rewarming. | |

*Critical care Clinical Guideline

Temperature Control after Cardiac Arrest Version 2.1 dated 26 Jan 14
**Management of re-warming**

*If patients present hypothermic, warm to 36°C no faster than 0.5°C /hr. Aim to re-warm by 0.5°C per hour if possible using IV cooling device if it is in situ.*

* At 30 hrs of therapeutic normothermia, turn on ventilator heater/humidifier

*Passive re-warming by removing ice packs or jacket if used as method for cooling

*Cease sedative drugs at 30 hrs and assess neurological function and patient safety. Recomence if indicated.

*Continued cooling at 36°C to maintain normothermia is likely to be necessary in the first 24 hours post re-warming, due to the risks of rebound hyperthermia. Use the graph function to see how hard the CoolGuard is working to achieve normothermia.

*'Icycath' device should be removed once IV temperature control and re-warming is complete and replaced with CVC if necessary. This may be 24-48h after re-warming if there has been rebound hyperthermia, i.e 72h total. Consultant approval is required to use the line for longer.

Guidelines as per ILCOR, ERC and AHA recommendations\(^6,7,8\)

To prevent or treat rebound hyperthermia\(^8\) A faster rate of rewarming has been associated with poorer outcome.

To reduce risks associated with rebound hyperthermia (further brain damage can occur with rebound hyperthermia)\(^6\)

To reduce risk of infection/bleeding.

Manufacturers recommendations.

---

7. **TRAINING REQUIREMENTS**

All members of medical and nursing staff, who would be required to manage the care of patients following cardiac arrest, will be given training on appropriate methods available to achieve active cooling in critically ill patients, subsequent clinical care and re-warming procedures. Staff will be shown this guideline and how to access it via Critical Care online resources.

8. **MONITORING COMPLIANCE WITH, AND THE EFFECTIVENESS OF, PROCEDURAL DOCUMENTS**

This guideline will be reviewed initially at 6 months and thereafter 2 yearly by the DCCQ Guidelines Group. Measurement of compliance will be achieved by unit-based audit. Results reviewed will be fed back to members of the senior medical /nursing team and the Critical Care Governance Group.
9. REFERENCES AND ASSOCIATED DOCUMENTATION


TTM trial reference.


10. Cardioplegia reference


Appendix A

Neuroprognostication of Cooled Arrest Survivors

Bouwes et al in a study of 391 comatose adult arrest survivors treated with therapeutic hypothermia (TH), found that motor response (MR) gave a false outcome prediction in up to 15% of patients. This confirms other studies that showed MR at 72h gave false positive rates (FPR) of 12-24% for poor prognosis. Full motor recovery may take up to 6 days post cardiac arrest, with sedation and TH as potential confounders. Brainstem reflexes have a higher predictive value than motor responses, but even absent corneal/papillary reflexes may have a FPR of 4-6%. Early myoclonus has a FPR of 3-10% for poor prognosis.

A continuous EEG pattern, without flat periods or burst suppression during hypothermia has been associated with regain of consciousness. Non-reactive EEG background upon painful stimulation is associated with poor recovery. Reactive EEG background is a positive sign. Adding EEG to standard neurological examination improves outcome prediction as early as 12-24h post arrest.

Somato-sensory evoked potentials (SSEP) are usually used to confirm a bad prognosis of coma after arrest/TH at 48h. Except in very rare cases, absent bilateral N20s are invariably associated with irreversible coma and poor prognosis (FPR 0-2%). Preserved SSEP is not necessarily associated with a good prognosis. The predictive value of EEG reactivity is superior to SSEP.

For patients in the grey zone with coma but present N20s, a multimodal approach is recommended.

High Neuron Specific Enolase (NSE) is a marker of acute brain damage. Patients with NSE greater than 33 mcg/l at 48-72h may still recover with good long term recovery. Cut off NSE level with FPR of 0% is 78-97 mcg/l. NSE is available (5ml, yellow tube) for £15.40 from Sheffield, via our labs, but takes 3 days for the result.

A subset of patients who have late seizures after the rewarming phase but display EEG reactivity and brainstem activity may survive with good neurological recovery and warrant aggressive therapy with anticonvulsants.

There is currently no evidence to support choice of first line anticonvulsant. Valproate, levotiracetam and phenytoin are widely used according to avoiding their side effects, with approx 60% efficacy in hypoxic brain damage. Addition of a 2nd agent has a limited efficacy of a further 10% or less and propofol should be considered.
Appendix B

Laerdal Medicool Kit – Instructions for Preparation and Use
(taken from Laderal Medicool instruction leaflet)

1. Each set has two sets of pads, one in white and one in blue.

2. Each set consists of;
   • A padded chest pad
   • Head bonnet
   • 2x pads for axillae
   • 2x pads for groin

3. Initially soak all pads individually in water for 30-35mins until crystal in pockets become a gel. Pads are now activated for use. Activated pads should be firm but not bursting. Use fingers to distribute gel evenly within pocket.

4. Towel off excess water

5. Place each activated pad in the plastic bags provided. Then place white and blue pad sets in individual plastic bag.

6. Place each pad set into the freezer for a minimum of 2 hours. (freezer located on west side of DCCQ)

7. When required place one set of cooling pads in the same colour, on the patient

8. When kit warms up (after approximately 2 hours) remove the kit from the patient and into the freezer in saved bags.

9. Apply second set of cooling pads onto patient from freezer

10. Continue to alternate kits as long as required.

11. Each kit is for single patient use only and may be discarded when cooling has ceased.
# Appendix C

**Checklist for the Review and Ratification of Procedural Documents and Consultation and Proposed Implementation Plan**

To be completed by the author of the document and attached when the document is submitted for ratification: a blank template can be found on the [Trust Intranet, Home page -> Policies -> Templates](#).

<table>
<thead>
<tr>
<th>CHECKLIST FOR REVIEW AND RATIFICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>TITLE OF DOCUMENT BEING REVIEWED:</td>
</tr>
<tr>
<td><strong>1 Title</strong></td>
</tr>
<tr>
<td>Is the title clear and unambiguous?</td>
</tr>
<tr>
<td>Will it enable easy searching/access/retrieval?</td>
</tr>
<tr>
<td>Is it clear whether the document is a policy, guideline, procedure, protocol or ICP?</td>
</tr>
<tr>
<td><strong>2 Introduction</strong></td>
</tr>
<tr>
<td>Are reasons for the development of the document clearly stated?</td>
</tr>
<tr>
<td><strong>3 Content</strong></td>
</tr>
<tr>
<td>Is there a standard front cover?</td>
</tr>
<tr>
<td>Is the document in the correct format?</td>
</tr>
<tr>
<td>Is the purpose of the document clear?</td>
</tr>
<tr>
<td>Is the scope clearly stated?</td>
</tr>
<tr>
<td>Does the scope include the paragraph relating to ability to comply, in the event of an infection outbreak, flu pandemic or any major incident?</td>
</tr>
<tr>
<td>Are the definitions clearly explained?</td>
</tr>
<tr>
<td>Are the roles and responsibilities clearly explained?</td>
</tr>
<tr>
<td>Does it fulfill the requirements of the relevant Risk Management Standard? (see attached compliance statement)</td>
</tr>
<tr>
<td>Is it written in clear, unambiguous language?</td>
</tr>
<tr>
<td><strong>4 Evidence Base</strong></td>
</tr>
<tr>
<td>Is the type of evidence to support the document explicitly identified?</td>
</tr>
<tr>
<td>Are key references cited?</td>
</tr>
<tr>
<td>Are the references cited in full?</td>
</tr>
<tr>
<td>Are the references cited in full?</td>
</tr>
<tr>
<td>Are associated documents referenced?</td>
</tr>
<tr>
<td><strong>5 Approval Route</strong></td>
</tr>
<tr>
<td>Does the document identify which committee/group will approve it?</td>
</tr>
<tr>
<td><strong>6 Process to Monitor Compliance and Effectiveness</strong></td>
</tr>
<tr>
<td>Are there measurable standards or KPIs to support the monitoring of compliance with the effectiveness of the document?</td>
</tr>
<tr>
<td><strong>7 Review Date</strong></td>
</tr>
<tr>
<td>Is the review date identified?</td>
</tr>
<tr>
<td><strong>6 Dissemination and Implementation</strong></td>
</tr>
<tr>
<td>Is a completed proposed implementation plan attached?</td>
</tr>
<tr>
<td><strong>7 Equality and Diversity</strong></td>
</tr>
<tr>
<td>Is a completed Equality Impact Assessment attached?</td>
</tr>
<tr>
<td>CONSULTATION AND PROPOSED IMPLEMENTATION PLAN</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><strong>Date to ratification committee</strong></td>
</tr>
<tr>
<td><strong>Groups /committees / individuals involved in the development and consultation process</strong></td>
</tr>
<tr>
<td>DCCQ Guidelines Group</td>
</tr>
<tr>
<td>Critical Care Governance Group</td>
</tr>
<tr>
<td>Multidisciplinary staff working in DCCQ</td>
</tr>
<tr>
<td>(&amp; revised 13 Jan 14)</td>
</tr>
<tr>
<td><strong>Is training required to support implementation?</strong></td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td><strong>If yes, outline plan to deliver training</strong></td>
</tr>
<tr>
<td>Multidisciplinary teaching via unit based teaching teams, regular teaching sessions on Fridays and bedside teaching from experienced staff</td>
</tr>
<tr>
<td><strong>Outline any additional activities to support implementation</strong></td>
</tr>
<tr>
<td>Promotion of introduction of guideline via unit based webpage and verbally through presentation at teaching sessions</td>
</tr>
</tbody>
</table>

**Individual Approval**

If, as the author, you are happy that the document complies with Trust policy, please sign below and send the document, with this paper, the Equality Impact Assessment and NHSLA checklist (if required) to the chair of the committee/group where it will be ratified. To aid distribution all documentation should be sent electronically wherever possible.

<table>
<thead>
<tr>
<th>Name</th>
<th>Dr David Pogson</th>
<th>Date</th>
<th>10 May 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signature</td>
<td>signed electronically (&amp; revised 13 Jan 14)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Committee / Group Approval**

If the committee/group is happy to ratify this document, would the chair please sign below and send the policy together with this document, the Equality Impact Assessment, and NHSLA checklist (if required) and the relevant section of the minutes to the Trust Policies Officer. To aid distribution all documentation should be sent electronically wherever possible.

<table>
<thead>
<tr>
<th>Name</th>
<th>Dr Nick Tarmey</th>
<th>Date</th>
<th>10 May 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signature</td>
<td>signed electronically (&amp; revised 13 Jan 14)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If answers to any of the above questions is ‘no’, then please do not send it for ratification.
Appendix D

**Equality Impact Assessment**

To be completed by the author of the document and attached when the document is submitted for ratification: a blank template can be found on the [Trust Intranet. Home page -> Policies -> Templates](#).

<table>
<thead>
<tr>
<th>Title of document for assessment</th>
<th>Therapeutic Cooling following Cardiac Arrest -DCCQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of assessment</td>
<td>02/04/2013 (revised 13 Jan 14)</td>
</tr>
<tr>
<td>Job title of person responsible for assessment</td>
<td>Dr D Pogson</td>
</tr>
<tr>
<td>Division/Service</td>
<td>DCCQ / CHAT CSC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Does the document affect one group less or more favorably than another on the basis of:</th>
<th>Yes/No</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Race</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Gender (including transgender)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Religion or belief</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Sexual orientation, including lesbian, gay and bisexual people</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Age (for HR policies only)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Disability – learning disabilities, physical disabilities, sensory impairment and mental health problems</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Does this document affect an individual’s human rights?</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>If you have identified potential discrimination, are the exceptions valid, legal and/or justified?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If the answers to any of the above questions is ‘yes’ you will need to complete a full Equality Impact Assessment (available from the Equality and Diversity website) or amend the policy such that only an disadvantage than can be justified is included. If you require any general advice please contact staff in the Equality and Diversity Department on 02392 288511.